Biotech play Alterity Therapeutics is seeking to raise about $40 million following a stellar set of Phase 2 results last week which sent the shares rocketing 50 per cent. Fund manager sources told ...

Alterity Therapeutics Limited, a pharmaceutical company specializing in the development of therapeutic drugs, has announced its compliance with the Takeovers Panel General Guidance Note 20. The ...

Alterity Therapeutics Limited (NASDAQ:ATHE), a pharmaceutical company specializing in the development of therapeutic drugs with a market capitalization of $42.92 million, has filed a notice with the ...

Benchmark analyst Robert Wasserman downgraded Alterity Therapeutics (ATHE) to Hold from Speculative Buy.Maximize Your Portfolio with Data ...

Maxim analyst Jason McCarthy raised the firm’s price target on Alterity Therapeutics (ATHE) to $12 from $8 and keeps a Buy rating on the shares ...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a ...

Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a ...

CD&R has named Sam Camens as managing director. In this role, Camens will drive CD&R’s health and welfare strategy. Previously, he was managing director of insurance and benefits at Onex. He is the ...

Alterity Therapeutics (NASDAQ:ATHE) announced Thursday that its lead candidate, ATH434, slowed clinical progression with a statistically significant impact in a mid-stage trial for patients with ...